Related Experiment Video
Updated: Jul 14, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses
Jochen Utikal1, Selma Ugurel, Hjalmar Kurzen
1Department of Dermatology, Venereology, and Allergology, Central Laboratory, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg, Germany. jutikal@mgh.harvard.edu
Background:
Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known.
Observations:
Herein, we report the case of a 41-year-old man with Rosai-Dorfman disease, a form of systemic non-Langerhans cell histiocytoses, with histiocytic infiltrations in the skin, bone marrow, liver, and spleen. Histiocytes were positive for the imatinib target proteins platelet-derived growth factor receptor beta and KIT. The disease completely responded to treatment with 400 to 600 mg daily of imatinib for more than 7 months.
Conclusion:
This case shows that imatinib is a powerful treatment option for patients with non-Langerhans cell histiocytoses.
